{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T10:34:51Z","timestamp":1782642891933,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bmc.2025.118477","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:09:48Z","timestamp":1761930588000},"page":"118477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity"],"prefix":"10.1016","volume":"133","author":[{"given":"Mai S.","family":"El-Shoukrofy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai E.","family":"Amr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek M.","family":"Okda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-Mohsen M.E.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omaima M.","family":"AboulWafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118477_bb0005","article-title":"Computational design, synthesis, and bioevaluation of 2-(pyrimidin-4-yl)oxazole-4-carboxamide derivatives: dual inhibition of EGFRWT and EGFRT790M with ADMET profiling","volume":"143","author":"Khedkar","year":"2024","journal-title":"Bioorg Chem"},{"issue":"12","key":"10.1016\/j.bmc.2025.118477_bb0010","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1021\/acsomega.3c09212","article-title":"Novel 2-aminobenzothiazole derivatives: docking, synthesis, and biological evaluation as anticancer agents. ACS","volume":"9","author":"Salih","year":"2024","journal-title":"Omega"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0015","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2025.118477_bb0020","first-page":"11","article-title":"Dual target of EGFR and mTOR suppresses triple-negative breast Cancer cell growth by regulating the phosphorylation of mTOR downstream proteins","volume":"15","author":"Ma","year":"2023","journal-title":"Breast Cancer: Targets and Therapy"},{"key":"10.1016\/j.bmc.2025.118477_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106496","article-title":"Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: design, synthesis and biological evaluation","volume":"135","author":"Amin","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107607","article-title":"Aromatase inhibitors for the treatment of breast cancer: an overview (2019\u20132023)","volume":"151","author":"Bhatia","year":"2024","journal-title":"Bioorg Chem"},{"issue":"9","key":"10.1016\/j.bmc.2025.118477_bb0035","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.62347\/KIVS3169","article-title":"Receptor tyrosine kinases in breast cancer treatment: unraveling the potential","volume":"14","author":"Qi","year":"2024","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.bmc.2025.118477_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107185","article-title":"Novel pyrimidine-5-carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFRWT\/T790M and PI3k enzymes: design, synthesis, biological evaluation, and docking studies","volume":"145","author":"Reda","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108563","article-title":"Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFRL858R\/T790M inhibitors and nitric oxide donors with dual anti-inflammatory\/anti-proliferative activities","volume":"161","author":"Fadaly","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108728","article-title":"Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity","volume":"163","author":"Aboelez","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers (2017\u2013)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"32","key":"10.1016\/j.bmc.2025.118477_bb0060","doi-asserted-by":"crossref","first-page":"34358","DOI":"10.1021\/acsomega.4c01361","article-title":"Design and synthesis of new dihydropyrimidine derivatives with a cytotoxic effect as dual EGFR\/VEGFR-2 inhibitors","volume":"9","author":"Al-Wahaibi","year":"2024","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14756366.2021.2010729","article-title":"Design, synthesis, and biological evaluation of new thieno[2,3-d]pyrimidine derivatives as targeted therapy for PI3K with molecular modelling study","volume":"37","author":"Elmenier","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107077","article-title":"A comprehensive review of small molecules targeting PI3K pathway: exploring the structural development for the treatment of breast cancer","volume":"143","author":"Dubey","year":"2024","journal-title":"Bioorg Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118477_bb0075","first-page":"185","article-title":"The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts","volume":"1870","author":"McKenna","year":"2018","journal-title":"BBA Rev Cancer"},{"issue":"10","key":"10.1016\/j.bmc.2025.118477_bb0080","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543776.2021.1924150","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016\u20132020)","volume":"31","author":"Sabbah","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2025.118477_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116109","article-title":"Advancements in dual-target inhibitors of PI3K for tumor therapy: clinical progress, development strategies, prospects","volume":"265","author":"Hu","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118477_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14737140.2015.961429","article-title":"PI3K\/AKT\/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?","volume":"15","author":"Abraham","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/biom13010093","article-title":"PI3K\u2013AKT-targeting breast cancer treatments: natural products and synthetic compounds","volume":"13","author":"Yuan","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118477_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114183","article-title":"Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): preclinical and clinical evidences","volume":"159","author":"Ye","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2025.118477_bb0110","article-title":"Biological activity and ADME\/tox prediction of some 2-substituted benzoxazole derivatives","volume":"123","author":"Foto","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103382","article-title":"In-vitro anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors","volume":"94","author":"Desai","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103593","article-title":"Benzoxazole derivatives as new generation of anti-breast cancer agents","volume":"96","author":"Omar","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104752","article-title":"Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells","volume":"109","author":"Omar","year":"2021","journal-title":"Bioorg Chem"},{"issue":"21","key":"10.1016\/j.bmc.2025.118477_bb0130","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/cmdc.202100370","article-title":"A patent review on the current developments of benzoxazoles in drug discovery","volume":"16","author":"Wong","year":"2021","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115215","article-title":"Pyrazolopyrimidine library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K\/mTOR pathway","volume":"28","author":"Valero","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106799","article-title":"Novel 4-(2-arylidenehydrazineyl)thienopyrimidine derivatives as anticancer EGFR inhibitors: design, synthesis, biological evaluation, kinome selectivity and in silico insights","volume":"140","author":"Elsebaie","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136903","article-title":"Synthesis, characterization, biological evaluation and in silico studies of novel 1,3,4-thiadiazole derivatives as aromatase inhibitors","volume":"1296","author":"Demiraran","year":"2024","journal-title":"J Mol Struct"},{"issue":"42","key":"10.1016\/j.bmc.2025.118477_bb0150","doi-asserted-by":"crossref","first-page":"29070","DOI":"10.1039\/D3RA03483F","article-title":"EGFR and PI3K\/m-TOR inhibitors: design, microwave assisted synthesis and anticancer activity of thiazole\u2013coumarin hybrids","volume":"13","author":"Batran","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118477_bb0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejmech.2012.10.017","article-title":"Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors","volume":"61","author":"Mowafy","year":"2013","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2025.118477_bb0160","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/pharmaceutics14081558","article-title":"Acetic acid mediated for one-pot synthesis of novel pyrazolyl s-triazine derivatives for the targeted therapy of triple-negative breast tumor cells (MDA-MB-231) via EGFR\/PI3K\/AKT\/mTOR signaling cascades","volume":"14","author":"Shawish","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/ph16010097","article-title":"Design, synthesis, and biological evaluation of 2-mercaptobenzoxazole derivatives as potential multi-kinase inhibitors","volume":"16","author":"Alanazi","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01404408","article-title":"A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures","volume":"11","author":"Edmondson","year":"1988","journal-title":"J Tissue Cult Methods"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0175","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1080\/14756366.2022.2081844","article-title":"Design, synthesis, molecular modeling and biological evaluation of novel benzoxazole-benzamide conjugates via a 2-thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers","volume":"37","author":"Eissa","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.bmc.2025.118477_bb0185","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.bmc.2016.05.063","article-title":"Toward discovery of mutant EGFR inhibitors; design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives","volume":"24","author":"Mowafy","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2025.118477_bb0190","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.3390\/ijms23094800","article-title":"The divergent effects of ovarian steroid hormones in the MCF-7 model for luminal a breast cancer: mechanistic leads for therapy","volume":"23","author":"Telan","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bmc.2025.118477_bb0195","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1080\/15548627.2015.1100930","article-title":"A pivotal role of FOS-mediated BECN1\/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation","volume":"11","author":"Wang","year":"2015","journal-title":"Autophagy"},{"issue":"6","key":"10.1016\/j.bmc.2025.118477_bb0200","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/med.21580","article-title":"Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives","volume":"39","author":"Sun","year":"2019","journal-title":"Med Res Rev"},{"issue":"12","key":"10.1016\/j.bmc.2025.118477_bb0205","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3390\/molecules29122919","article-title":"Halogenated boroxine K2[B3O3F4OH] modulates metabolic phenotype and autophagy in human bladder carcinoma 5637 cell line","volume":"29","author":"Elez-Burnjakovi\u0107","year":"2024","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.bmc.2025.118477_bb0210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4161\/auto.7.8.15598","article-title":"Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis","volume":"7","author":"Lee","year":"2011","journal-title":"Autophagy"},{"issue":"11","key":"10.1016\/j.bmc.2025.118477_bb0215","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.3390\/cancers13112618","article-title":"Therapeutics targeting the core apoptotic machinery","volume":"13","author":"Hamilton","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2025.118477_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/0471143030.cb1808s21","article-title":"Flow cytometry of apoptosis","volume":"21","author":"Pozarowski","year":"2003","journal-title":"Curr Protoc Cell Biol"},{"issue":"2","key":"10.1016\/j.bmc.2025.118477_bb0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/adt.2021.140","article-title":"Modifications to the Transwell migration\/invasion assay method that eases assay performance and improves the accuracy","volume":"20","author":"Stoellinger","year":"2022","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.bmc.2025.118477_bb0235","series-title":"ARO active site: PDB ID: 3EQM. Accessed 15 March 2025","year":"2025"},{"issue":"7226","key":"10.1016\/j.bmc.2025.118477_bb0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature07614","article-title":"Structural basis for androgen specificity and estrogen synthesis in human aromatase","volume":"457","author":"Gosh","year":"2009","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bmc.2025.118477_bb0245","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.steroids.2011.02.037","article-title":"Binding features of steroidal and nonsteroidal inhibitors","volume":"76","author":"Hong","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.bmc.2025.118477_bb0250","series-title":"EGFRWT active site: PDB ID: 1XKK. Accessed 15 March 2025","year":"2025"},{"issue":"18","key":"10.1016\/j.bmc.2025.118477_bb0255","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib) relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118477_bb0260","series-title":"EGFRL858R active site: PDB ID: 2ITZ. Accessed 20 March 2025","year":"2025"},{"issue":"3","key":"10.1016\/j.bmc.2025.118477_bb0265","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bmc.2025.118477_bb0270","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/biom9030082","article-title":"Structural determinants of isoform selectivity in PI3K inhibitors","volume":"9","author":"Miller","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118477_bb0275","series-title":"PI3K\u03b1 active site: PDB ID: 4ZOP. Accessed 11 April 2025","year":"2025"},{"key":"10.1016\/j.bmc.2025.118477_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106352","article-title":"Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via AuroraA\/PI3K\/BRD4 inhibition","volume":"132","author":"Fan","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0285","series-title":"PI3K\u03b2 active site: PDB ID: 2Y3A. Accessed 15 April 2025","year":"2025"},{"issue":"5","key":"10.1016\/j.bmc.2025.118477_bb0290","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molcel.2011.01.026","article-title":"Structure of lipid kinase p110\u03b2\/p85\u03b2 elucidates an unusual SH2-domain-mediated inhibitory mechanism","volume":"41","author":"Zhang","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2025.118477_bb0295","series-title":"PI3K\u03b3 active site: PDB ID: 3DBS. Accessed 15 April 2025","year":"2025"},{"issue":"18","key":"10.1016\/j.bmc.2025.118477_bb0300","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0305","series-title":"PI3K\u03b4 active site: PDB ID: 2WXP. Accessed 15 April 2025","year":"2025"},{"issue":"2","key":"10.1016\/j.bmc.2025.118477_bb0310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nchembio.293","article-title":"The p110\u03b4 structure: mechanisms for selectivity and potency of new PI(3)K inhibitors","volume":"6","author":"Berndt","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2025.118477_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111786","article-title":"6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: design, synthesis and structure-activity relationship studies","volume":"185","author":"Toolabi","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118477_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107403","article-title":"Discovery of novel pyrazole based urea\/thiourea derivatives as multiple targeting VEGFR-2, EGFRWT, EGFRT790M tyrosine kinases and COX-2 inhibitors, with anti-cancer and anti-inflammatory activities","volume":"147","author":"Fadaly","year":"2024","journal-title":"Bioorg Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118477_bb0335","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/cells12071080","article-title":"Photobiomodulation at 660 nm stimulates in vitro diabetic wound healing via the Ras\/MAPK pathway","volume":"12","author":"Kasowanjete","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bmc.2025.118477_bb0350","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/14756366.2021.1901089","article-title":"Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","volume":"36","author":"Kassab","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2025.118477_bb0355","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.62347\/NZIJ5785","article-title":"PPIH as a poor prognostic factor increases cell proliferation and m6A RNA methylation in hepatocellular carcinoma","volume":"14","author":"Chi","year":"2024","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.bmc.2025.118477_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139330","article-title":"Synthesis, biological screening, and binding mode analysis of some N-substituted tetrahydroquinoline analogs as apoptosis inducers and anticancer agents","volume":"1318","author":"Dey","year":"2024","journal-title":"J Mol Struct"},{"issue":"11","key":"10.1016\/j.bmc.2025.118477_bb0365","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231568","article-title":"Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension","volume":"221","author":"Niihori","year":"2024","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.bmc.2025.118477_bb0370","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/biom11050671","article-title":"Comparison of anticancer activity of Dorycnium pentaphyllum extract on MCF-7 and MCF-12A cell line: correlation with invasion and adhesion","volume":"11","author":"Koygun","year":"2021","journal-title":"Biomolecules"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:39:30Z","timestamp":1781253570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":69,"alternative-id":["S0968089625004183"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118477","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118477"}}